Eli Lilly and Company

Pharmaceuticals for the treatment of human disease, tissue regeneration and repair.

Eli Lilly and Company was founded in May 1876 by Colonel Eli Lilly in Indianapolis, Ind. and is a research-based pharmaceutical industry. The research division, Lilly Research Laboratories (LRL), is responsible for the discovery, development and clinical evaluation of potential new pharmaceutical products.

Sidney Taurel, CEO
Robert Armitage, Senior VP and General Counsel
Alan Breier, VP, Medical and CMO
John Lechleiter, President and COO

Sidney Taurel, Chair
Sir Winfried Bischoff
J. Michael Cook
Martin S. Feldstein
George M.C. Fisher
J. Erik Fyrwald
Alfred G. Gilman
Karen N. Horn
John C. Lechleiter, Ph.D.
Ellen R. Marram
Franklyn G. Prendergast
Kathi P. Seifert

Lilly Corporate Center
Indianapolis, IN 46285
USA
Phone: +1-317-276-2000

Goal of the research group of Dr. Smith is to develop new pharmaceuticals for the treatment of human disease, particularly novel therapies that will aid human tissue regeneration and repair. In collaboration with the Centre for Regenerative Biology and Medicine, Indianapolis, USA, the scientists have used the frog Xenopus laevis to identify genes that are involved in limb regeneration. Because of mammalian homologues of these genes, the research group is exploring the role and potential therapeutic utility of these genes in mammalian tissue repair.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.